SCHEMBL1156789

SCHEMBL1156789

Cc1ccc(S(=O)(=O)n2cc(CN(CC(C)(C)C)C(=O)O)cc2Br)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TSHR P16473 1/20 0.39
OPRK1 P41145 2/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
MAPT P10636 2/20 0.37
GAA P10253 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KCNA5 P22460 1/20 0.36
ALK Q9UM73 1/20 0.36
VEGFA P15692 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1156624 0.91 CHRM5 (0.43) LMNAL3MBTL1SMN1; SMN2POLBCHRM5
SCHEMBL1156885 0.90 PTGDR2 (0.40) LMNAOPRK1PTGDR2MAPTALDH1A1
SCHEMBL4411754 0.89 CHRM5 (0.42) LMNAL3MBTL1SMN1; SMN2POLBCHRM5
SCHEMBL1157013 0.89 CHRM5 (0.46) L3MBTL1PTGDR2CHRM5
SCHEMBL1278234 0.87 PTGDR2 (0.35) LMNAL3MBTL1KDM4ETSHRPTGDR2
SCHEMBL1156488 0.84 CHRM5 (0.36) L3MBTL1PTGDR2GAAALDH1A1POLB
SCHEMBL1156564 0.83 LMNA (0.41) LMNAPTGDR2ALDH1A1CHRM5
SCHEMBL4569737 0.83 PTGDR (0.42) LMNATSHRPTGDR2ALDH1A1PKM
SCHEMBL1278354 0.83 TAS2R14 (0.40) LMNAKDM4EALDH1A1CHRM5
SCHEMBL1156024 0.83 MAPT (0.46) LMNAL3MBTL1KDM4ETSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048909-B2 Proton pump inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-01 US disclosed
EP-2336107-A2 Proton pump inhibitors Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed
US-20110028476-A1 PROTON PUMP INHIBITORS KAJINO MASAHIRO 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028476-A1 PROTON PUMP INHIBITORS HRH2, HRH4, CYP2C19 LMNA 3735/4885L3MBTL1 3593/4885KDM4E 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.